Meiji Yasuda Asset Management Co Ltd. Boosts Stake in Humana Inc. (NYSE:HUM)

Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Humana Inc. (NYSE:HUM) by 6.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,502 shares of the insurance provider’s stock after buying an additional 149 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Humana were worth $935,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of HUM. Pzena Investment Management LLC boosted its position in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after purchasing an additional 1,955,375 shares in the last quarter. Davis Selected Advisers boosted its position in Humana by 16.1% during the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after purchasing an additional 321,233 shares in the last quarter. Sanders Capital LLC purchased a new stake in Humana during the fourth quarter worth $489,300,000. Ontario Teachers Pension Plan Board boosted its position in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after purchasing an additional 1,050,459 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Humana by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,018,248 shares of the insurance provider’s stock worth $380,368,000 after purchasing an additional 20,891 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of NYSE:HUM opened at $312.00 on Friday. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The business has a 50-day moving average of $359.14 and a two-hundred day moving average of $345.90. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The firm has a market capitalization of $37.60 billion, a PE ratio of 19.43, a P/E/G ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the prior year, the business earned $8.94 earnings per share. The company’s revenue was up 10.4% compared to the same quarter last year. As a group, research analysts forecast that Humana Inc. will post 16 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.13%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s payout ratio is 22.04%.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of research analyst reports. Baird R W upgraded Humana to a “hold” rating in a research report on Thursday, May 30th. TD Cowen boosted their target price on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Piper Sandler began coverage on Humana in a report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, September 10th. Finally, Robert W. Baird began coverage on Humana in a report on Thursday, May 30th. They issued a “neutral” rating and a $374.00 price target for the company. Thirteen analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $398.70.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.